#ASH22: Regeneron claims it has set a 'new benchmark' in follicular lymphoma

Kyle LaHucik

Senior Reporter

NEW ORLEANS — Regeneron gave researchers a first look at interim results from its Phase II study of a CD20xCD3 bispecific antibody in patients with relapsed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASH22: Regeneron claims it has set a 'new benchmark' in follicular lymphoma

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Federal appeals court says Teva must delist Orange Book inhaler patents

#ASH22: Re­gen­eron claims it has set a 'new bench­mark' in fol­lic­u­lar lym­phoma

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Fed­er­al ap­peals court says Te­va must delist Or­ange Book in­haler patents

#ASH22: Regeneron claims it has set a 'new benchmark' in follicular lymphoma

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Federal appeals court says Teva must delist Orange Book inhaler patents